Intelligence

Home / Intelligence

Type
  • All
  • Blog
  • Briefs
  • Case Studies
  • Podcasts
  • Scientific Publications
  • Webinars
  • White Papers
Featured Topic
  • All
  • AIML
  • Analytics
  • APAC
  • Benchmarking
  • Biosimilars
  • CAR-T
  • Cell and Gene Therapy
  • Commercial Operations
  • Competitive Intelligence
  • Contract Analytics
  • Corporate Strategy
  • COVID-19
  • Data Management
  • Digital Therapeutics
  • Diversity
  • Dynamic Market Intelligence
  • Emerging Life Sciences
  • Europe
  • Evidence Strategy (HEOR)
  • Field Force
  • Forecasting
  • Generative AI
  • Incentive Compensation
  • Inflation Reduction Act
  • Insights
  • International
  • LatAm
  • Launch and Brand Excellence
  • Learning and Development
  • Market Research
  • Marketing
  • MedTech
  • New Product Planning
  • NRDL
  • Omnichannel
  • Oncology
  • Patient Centricity
  • Patient Finding
  • Patient Services
  • Performance Tracking
  • Pricing and Access
  • Product Demos
  • Rare Disease
  • Real-World Evidence
  • Scientific Publications
  • Talent Acquisition and Retention
  • United States
Search

Webinars

Omnichannel Orchestration After Patient Finding: Once You’ve Found The Patients, What Do You Do?

March 7, 2024 | 1:00 - 1:45 PM ET

Join Susheel Sukhtankar as he hosts a dynamic discussion on the nuances of omnichannel orchestration with panelists Jerry Luciano and Anushank Anand.

Sign Up Now

Scientific Publications

Describing the Clinical Approach to Diagnosis and Treatment of Patients with Hypoactive Sexual Desire Disorder

Hypoactive sexual desire disorder (HSDD) is the most prevalent form of female sexual dysfunction (FSD) in the United States and is characterized by a decrease or lack of sexual desire accompanied by distress. Despite the relatively high prevalence of HSDD in US women 18-44 years of age (∼10%), there is a limited understanding of the condition among physicians. Authors Sharon Parish, Zainab Shahpurwala, Amod Athavale, Rahul Ravindranath, Nandini Hadker, and Michelle Lim-Watson Journal ISSWSH / ISSM Joint Meeting, March 2019…

Read Now

White Papers

2019 Trinity Drug Index

The annual Trinity Drug Index provides a comprehensive evaluation of the performance of drugs by therapeutic value, commercial performance and R&D complexity. By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose…

Read Now

Briefs

Making the Leap From Pharma to Pre-Commercial: A Field Guide for the New CCO

By Curt Staab, TGaS® Advisors, a division of Trinity Executive Summary TGaS® Advisors’ Emerging Life Sciences Network (elsN) has gathered advice and lessons learned from a broad-based CCO peer network to create this guide, the first in a series designed to help CCOs manage day-to-day and for the long-term. In this White Paper, we provide an overview of a CCO’s responsibilities, resources and expectations. Future issues will offer advice from peers and experts on launch planning and hiring. To learn more,…

Read Now

Scientific Publications

Patient Frailty and the Burden of Overactive Bladder

Age and frailty are risk factors for overactive bladder (OAB), but less is known about their association with OAB burden. Authors Amod Athavale, Marissa Suh, Ali Haber, Jillian Godfrey Scaife, Nandini Hadker, Katherine Gooch Journal AGS Annual Meeting, May 2019 View publication…

Read Now

Scientific Publications

Unmet Need Associated With Available Therapeutic Options For Management Of Dyspareunia Related To Genitourinary Syndrome Of Menopause: A Systematic Literature Review

Genitourinary syndrome of menopause (GSM) is a chronic, progressive condition affecting up to 60% of post-menopausal women in the United States. Dyspareunia, or pain with sexual intercourse, has been recognized as one of GSM’s most bothersome symptoms. Despite high prevalence and availability of treatments, many women are not adequately managed, and unmet need remains. The objective of this systematic literature review was to characterize the unmet need. Authors S.S. Faubion, S.S. Karkare, K.R. Hennegan, N. Hadker, B.R. Robinson, M.Z. Lim-Watson…

Read Now

Scientific Publications

Predicting Hypoparathyroidism Diagnosis In Medicare Claims — Exploring The Utility Of Sequence Analysis

Claims-based prediction models commonly use dichotomous indicator variables (e.g., presence/absence of disease) or count variables (e.g., frequency of claims) as predictors. The research objective was to compare the predictive ability of this standard model with other models that account for the sequence of events. The models were applied in the context of predicting hypoparathyroidism diagnosis among Medicare beneficiaries. Authors Site Li, Bingqing Yu, Xinyi Wang, Guangyan Yu, Diptanshu Singh, Gavin Miyasato, Masanao Yajima Journal ISPOR Meeting, May 2019 View publication…

Read Now

Scientific Publications

Assessing Healthcare Resource Utilization Across Segments of Obesity — A Retrospective Claims Study

Obesity is a disease that is caused and influenced by genes and the environment. Whether different etiologies or presentations of obesity result in homogeneous disease burden and/or cost is not well characterized. The objective is to determine whether there are distinct segments within the pool of patients who are obese that are differentiated by clinical characteristics, and quantify their healthcare resource utilization (direct healthcare costs [HCC]), using U.S. claims data. Authors Marissa Suh, Monica Fay, Amy McCagg, Ida Moeller, Scott…

Read Now

White Papers

How to Approach Asset Valuation in Pharma & Biotech:

Pharma and biotech companies are innovation drivers at the frontlines of research and development. To fund and support this promising science, there is a great need for partnerships and mergers and acquisitions (M&A) to drive the growth/pipeline of the industry. For these collaborative relationships to occur, understanding the value of a company’s underlying assets is of the utmost importance. Since Trinity’s founding, multiple pharma and biotech clients have relied on its expertise in forecast and valuing assets. These engagements have…

Read Now

Sign up for the latest intelligence

By signing up, you are agreeing to our Privacy Policy.

By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.